Histrelin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Histrelin
- Histrelin: From a GnRH Agonist Implant (Original Indication Not Recorded) to Ambras Type Hypertrichosis Universalis Congenita
Histrelin: From a GnRH Agonist Implant (Original Indication Not Recorded) to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Histrelin is a GnRH agonist marketed in the US as the SUPPRELIN implant. The source data does not record its original indication. The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but there are 0 clinical trials and 0 publications supporting this direction. The prediction appears to be a knowledge-graph artifact rather than a biological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the source data |
| Predicted New Indication | Ambras type hypertrichosis universalis congenita |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the record. Histrelin is a GnRH agonist. Sustained receptor stimulation desensitizes the pituitary and suppresses LH/FSH and downstream sex steroids.
That mechanism does not fit this indication well. Ambras syndrome is a congenital hair disorder linked to chromosome 8q22 rearrangements affecting TRPS1 regulation. It is not driven by the pituitary-gonadal axis, so GnRH suppression has no clear target.
The very high TxGNN score (0.9999) most likely reflects graph-neighbor effects, with hair-related diseases clustering near the drug in the knowledge graph. It does not reflect a real therapeutic link.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA022058 | SUPPRELIN | Implant | Not provided in the source data |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction has no trials, no literature, and no plausible mechanism. It is a model-only signal (L5) and should not be pursued.
Among the other predictions for this drug, only idiopathic central precocious puberty (rank 10, L3) has histrelin-specific literature. It consists of a pharmacology review, a single-surgeon implant series, and a reproductive axis follow-up study, with no RCTs. This is a well-established GnRH agonist use, so it may already be a labeled indication rather than true repurposing. Central precocious puberty 1 (rank 6, L4) also has a strong mechanistic fit but no direct evidence of its own.
To proceed, the following is needed:
- The approved indication text for NDA022058, to establish the original indication and check whether the precocious puberty entries are already on-label
- Package insert warnings and contraindications, which are currently a blocking gap for safety screening
- Detailed mechanism of action data from DrugBank
- A recommendation to re-center this report on the idiopathic central precocious puberty prediction, since the rank 1 hypertrichosis prediction has no supporting evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.